The Analysis of Malignancy by Cell Fusion: The Position in 1988

Cancer Research

Volumn 48, Issue 12, 1986, Pages 3302-3306

  Harris, Henry ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CELL FUSION; CHROMOSOME; CHROMOSOME ABERRATION; HEREDITY; HUMAN; METHODOLOGY; NONHUMAN; REVIEW;

CELL FUSION; CHROMOSOMES; GENES; GENETIC COMPLEMENTATION TEST; HUMAN; NEOPLASMS; ONCOGENES;

EID: 0023917947     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Croce, C. M., Barrick, J., Linnenbach, A., and Koprowski, H. Expression of malignancy in hybrids between normal and malignant cells. J. Cell. Physiol., 99:279-286, 1979.
2. Benedict, W. F., Weissman, B. E., Mark, C., and Stanbridge, E. J. Tumorigenicity of human HT1080 fibrosarcoma x normal fibroblast hybrids: chromosome dosage dependency. Cancer Res., 44: 3471-3479,1984.
3. Miller, D. A., and Miller, O. Chromosomes and cancer in the mouse: studies in tumors, established cell lines, and cell hybrids. Adv. Cancer Res., 39:153-182, 1983.
4. Sager, R. Genetic suppression of tumor formation. Adv. Cancer Res., 44: 43–68, 1985.
5. Harris, H. The genetic analysis of malignancy. J. Cell Sci., 4 (Suppl.): 431–444, 1986.
6. Stanbridge, E. J. Genetic regulation of tumorigenic expression in somatic cell hybrids. In: G. Klein (ed.), Advances in Viral Oncology, Vol. 6. New York: Raven Press, 1987.
7. Klinger, H. P., Kaelbling, M., and O'Hara, B. M. Suppressors of tumorigenicity. Genetic deregulation as one of the critical events in malignant transformation—a working hypothesis. In Vitro Cell Dev. Biol., 23: 58, 1987.
8. Evans, E. P., Burtenshaw, M. D., Brown, B. B., Hennion, R., and Harris, H. The analysis of malignancy by cell fusion. IX. Reexamination and clarification of the cytogenetic problem. J. Cell Sci., 56:113-130,1982.
9. Peehl, D. M., and Stanbridge, E. J. The role of differentiation in the suppression of tumorigenicity in human hybrid cells. Int. J. Cancer, 30:113-120, 1982.
10. Harris, H., and Bramwell, M. E. The suppression of malignancy by terminal differentiation: evidence from hybrids between tumour cells and keratinocytes. J. Cell Sci., 87:383-388, 1987.
11. Wiener, F., Klein, G., and Harris, H. The analysis of malignancy by cell fusion. V. Further evidence of the ability of normal diploid cells to suppress malignancy. J. Cell Sci., 15: 177–183, 1974.
12. Giacomoni, D. Tumorigenicity and intracisternal A-particle expression of hybrids between murine myeloma and lymphocytes. Cancer Res., 39:4481-4484, 1979.
13. Harris, H., and Klein, G. Malignancy of somatic cell hybrids. Nature (Lond.), 224:1314-1316, 1969.
14. Jonasson, J., Povey, S., and Harris, H. The analysis of malignancy by cell fusion. VII. Cytogenetic analysis of hybrids between malignant and diploid cells and of tumours derived from them. J. Cell Sci., 24:217-254, 1977.
15. Hitotsumachi, S., Rabinowitz, Z., and Sachs, L. Chromosomal control of reversion in transformed cells. Nature (Lond.), 231: 511–514, 1971.
16. Stoler, A., and Bouck, N. Identification of a single chromosome in the normal human genome essential for suppression of hamster cell transformation. Proc. Natl. Acad. Sci. USA, 82:570-574, 1985.
17. Lalley, P. A., Francke, U., and Minna, J. D. Homologous genes for enolase, phosphogluconate dehydrogenase, phosphoglucomutase, and adenylate kinase are syntenic on mouse chromosome 4 and human chromosome lp. Proc. Natl. Acad. Sci. USA, 75: 2382–2386, 1978.
18. Stanbridge, E. J., Flandermeyer, R. R., Daniels, D., and Nelson-Rees, W. A. Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. Somatic Cell Genet., 7:699-712, 1981.
19. Klinger, H. P. Suppression of tumorigenicity. Cytogenet. Cell Genet., 32: 68–84, 1982.
20. Kaelbling, M., and Klinger, H. P. Suppression of tumorigenicity in somatic cell hybrids. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intraspecies hybrids of normal diploid x malignant cells. Cytogenet. Cell Genet., 41:65-70, 1986.
21. Klinger, H. P., and Kaelbling, M. Suppression of tumorigenicity in somatic cell hybrids. IV. Chromosomes of normal human cells associated with suppression of tumorigenicity in hybrids with D98AH2 carcinoma cells. Cytogenet. Cell Genet., 42: 225–235, 1986.
22. Saxon, P. J., Srivatsan, E. S., and Stanbridge, E. J. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J., 5, 3461-3466,1986.
23. Weissman, B. E., Saxon, P. J., Pasquale, S. R., Jones, G. R., Geiser, A. G., and Stanbridge, E. J. Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Sciences (NY), 236:175-180, 1987.
24. Stanbridge, E. J., and Ceredig, R. Growth-regulatory control of human cell hybrids in nude mice. Cancer Res., 41: 573–580, 1981.
25. Harris, H. Suppression of malignancy in hybrid cells: the mechanism. J. Cell Sci., 79: 105–117, 1985.
26. Kaelbling, M., Roginski, R. S., and Klinger, H. P. DNA polymorphisms indicate loss of heterozygosity for chromosome 11 of D98AH2 cells. Cytogenet. Cell Genet., 41:240-244, 1986.
27. Dracopoli, N. C., Alhadeff, B., Houghton, A. N., and Old, L. J. Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res., 47: 3995-4000,1987.
28. Koufos, A., Hansen, M. F., Lampkin, B. C., Workman, M. L., Copeland, N. G., Jenkins, N. A., and Cavenee, W. K. Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature (Lond.), 309:170-172, 1984.
29. Orkin, S. H., Goldman, D. S., and Sallan, S. E. Development of homozygosity for chromosome 11p markers in Wilms' tumour. Nature (Lond.), 309: 172–174, 1984.
30. Fearon, E. R., Vogelstein, B., and Feinberg, A. P. Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours. Nature (Lond.), 309:176-178, 1984.
31. Koufos, A., Hansen, M. F., Copeland, N. G., Jenkins, N. A., Lampkin, B. C., and Cavenee, W. K. Loss of heterozygosity in three embryonal tumours suggests a common pathogenic mechanism. Nature (Lond.), 316: 330–334, 1985.
32. Zbar, B., Braugh, H., Talmadge, C., and Linehan, M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (Lond.), 327:721-724, 1987.
33. Fearon, E. R., Feinberg, A. P., Hamilton, S. H., and Vogelstein, B. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature (Lond.), 318: 377–380, 1985.
34. Roger, C. E., Sheridan, M., Su, C. Y., Shafritz, D. A., Summers, J., Shows, T. B., Henderson, A., and Kew, M. Deletions in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. Sciences (NY), 230: 319–322, 1985.
35. Ali, I. U., Lidereau, R., Theillet, C., and Callahan, R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Sciences (NY), 238:185-188, 1987.
36. Sparkes, R. S., Murphree, A. L., Lingua, R. W., Sparkes, M. C., Field, L. L., Funderburk, S. J., and Benedict, W. F. Gene for hereditary retinoblastoma assigned to human chromosome 13 by linkage to esterase D. Sciences (NY), 279:971-973, 1983.
37. Benedict, W. F., Murphree, A. L., Banerjee, A., Spina, C. A., Sparkes, M. C., and Sparkes, R. Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Sciences (NY), 219:973-975, 1983.
38. Cavenee, W. K., Hansen, M. F., Nordenskjold, M., Kock, E., Maumenee, I., Squire, J. A., Phillips, R. A., and Gallie, B. L. Genetic origin of mutations predisposing to retinoblastoma. Sciences (NY), 228:501-503, 1985.
39. Benedict, W. F., Srivatsan, E. R., Mark, C., Banerjee, A., Sparkes, R. S., and Murphree, A. L. Complete or partial homozygosity of chromosome 13 in primary retinoblastoma. Cancer Res., 47:4189-4191,1987.
40. Dryja, T. P., Rapaport, J. M., Epstein, J., Coorin, A. M., Weichselbaum, R., Koufos, A., and Cavenee, W. K. Chromosome 13 homozygosity in osteosarcoma without retinoblastoma. Am. J. Hum. Genet., 38:59-66, 1986.
41. Johnson, D. D., Dewald, G. W., Pierre, R. V., Letendre, L., and Silverstein, M. N. Deletions of chromosome 13 in malignant hematologic disorders. Cancer Genet. Cytogenet., 18:235-241, 1985.
42. Weiner, F., Cochran, A., Klein, G., and Harris, H. Genetic determinants of morphological differentiation in hybrid tumours. J. Natl. Cancer Inst., 48: 465–486, 1972.
43. Naylor, S. L., Johnson, B. E., Minna, J. D., and Sakaguchi, A. Y. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (Lond.), 329:451-454, 1986.
44. Kok, K., Osinga, J., Carritt, B., Davis, B. M., van der Hout, A. H., van der Veen, A. Y., Landsvater, R. M., de Leij, L. F. M. H., Berendsen, H. H., Postmus, P. E., Poppema, S., and Buys, C. H. C. M. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature (Lond.), 330:578-581, 1987.
45. Solomon, E., Voss, R., Hall, V., Bodmer, W. F., Jass, J. R., Jeffreys, A. J., Lucibello, F. C., Patel, I., and Rider, S. H. Chromosome 5 allele loss in human colorectal carcinomas. Nature (Lond.), 328:616-619, 1987.
46. Lau, C. C., Gadi, I. M., Kalvonjian, S., Anisowicz, A., and Sager, R. Plasmid-induced “hit-and-run” tumorigenesis in Chinese hamster embryo fibroblast (CHEF) cells. Proc. Natl. Acad. Sci. USA, 82: 2839–2843, 1985.
47. Stenman, G., Delorme, E. O., Lau, C. C., and Sager, R. Transfection with plasmid pSV2gptEJ induces chromosome rearrangements in CHEF cells. Proc. Natl. Acad. Sci. USA, 84:184-188, 1987.
48. Capon, D. J., Seeburg, P. H., McGrath, J. P., Hayflick, J. S., Edman, U., Levinson, A. D., and Goeddel, D. V. Activation of Ki-ras 2 gene in human colon and lung carcinomas by two different point mutations. Nature (Lond.), 304: 507–513, 1983.
49. Santos, E., Martin-Zanca, D., Reddy, E. P., Pierotti, M. A., Della Porta, G., and Barbacid, M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Sciences (NY), 223:661-664, 1984.
50. Klein, G., and Harris, H. Expression of polyoma-induced transplantation antigen in hybrid cell lines. Nature New Biol., 237: 163–164, 1972.
51. Dyson, P. J., Quade, K., and Wyke, J. A. Expression of the ASV src gene in hybrids between normal and virally transformed cells: specific expression occurs in some hybrids but not in others. Cell, 30:491-498, 1982.
52. Geiser, A. G., Der, C. J., Marshall, C. J., and Stanbridge, E. J. Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells. Proc. Natl. Acad. Sci. USA, 83:5209-5213,1986.
53. Harris, H., Miller, O. J., Klein, G., Worst, P., and Tachibana, T. Suppression of malignancy by cell fusion. Nature (Lond.), 223:363-368, 1969.